Protara Therapeutics’ (TARA) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright restated their buy rating on shares of Protara Therapeutics (NASDAQ:TARA – Free Report) in a report issued on Thursday morning,Benzinga reports. They currently have a $23.00 price objective on the stock. HC Wainwright also issued estimates for Protara Therapeutics’ FY2029 earnings at ($0.73) EPS. Separately, Guggenheim reaffirmed a “buy” rating and set a […]
HC Wainwright restated their buy rating on shares of Protara Therapeutics (NASDAQ:TARA – Free Report) in a report issued on Thursday morning,Benzinga reports. They currently have a $23.00 price objective on the stock. HC Wainwright also issued estimates for Protara Therapeutics’ FY2029 earnings at ($0.73) EPS. Separately, Guggenheim reaffirmed a “buy” rating and set a […]
